Skip to content

Speed with clarity.

Care without compromise.

Achieve clearer MRI brain scans. Maximize efficiency. Increase diagnostic confidence.

Contact Us
hero image

Improve the Neuroimages you get from the MRI machines you’re already using.

kV 120

mAs 250

TI 1.0

GT 12.5

SL 5.0/2x5.0

icon-more

Get more detail

Improve visualization and clarity.

icon-less-time

In less time

Thirty percent faster brain protocol times.

icon-decisions

For better decisions

Practical access to quantitative data.

Sharper images —powered by the physics of MRI

STAGE™ significantly improves the quality of the images from your current MRI machines. Our platform is powered by the physics of MRI—not AI—so you get fully sampled, 3D data you can trust.

Your STAGE™ for better MRI imaging

STAGE™ is the platform that improves the images from your MRI machines without extending scan times. In fact, with STAGE™, you can scan up to 40% faster while gaining enhanced visualization and the ability to collect quantitative data.

Faster scans, greater throughput

STAGE™ reduces the time for MRI brain protocols by 30% for your most common procedures, adding an extra 90–120 minutes of MRI scan time per day.

Clearer images, quantitative outputs

Get more from your images—much more. See greater detail. Gather quantitative data to help you measure disease progression with greater accuracy.

Works with a wide range of MRI machines

STAGE™ was developed independently of MRI manufacturers. It doesn’t require any hardware, so the platform can integrate seamlessly with virtually any machine.

Get on Stage

We work with some of the most respected partners in healthcare.

The SpinTech MRI advantage

MRI: Head scan

Ex:29942

Se:8

Im:4

Clinical advantages

The clinical advantages are clear: Reduce scan times. Provide better images for radiologists. Provide better information for neurologists and neurosurgeons. Deliver a better experience for patients.

Financial incentives

STAGE™ will transform your radiology department by streamlining workflows, improving patient throughput, increasing reimbursement, and elevating the patient experience.

STAGE™ has the most sensitive and robust techniques for quantifying the progression of Alzheimer’s and Parkinson’s diseases. For TBI, we can see four to five times more micro-hemorrhages and correlate that with outcomes.

Dr. Karen Tong

Neuroradiologist - Loma Linda University Hospital

STAGE™ software enables our imaging center to detect TBI and microbleeds with both greater precision and speed. It’s essential information for helping patients obtain the correct diagnosis and get the ongoing care they require.

Ron Mallilo

Director of Operations - All County Radiology

News

All News

News

ASN 2023: The Arrival of Practical QSM Tools Enhanced for Everyday Clinical Practice

Attendees at this year’s American Society of Neuroimaging annual meeting will have their first opportunity to see and hear how quantitative MRI (qMRI) and quantitative susceptibility mapping (QSM) tools are now practical for – and being used in — everyday clinical practice. QSM is just one of the advanced outputs available with STAGE and is“ASN 2023: The Arrival of Practical QSM Tools Enhanced for Everyday Clinical Practice”

read more

News

Health system priorities for AI and two important questions for radiology leaders

A new report from UPMC’s Center for Connected Medicine and KLAS Research about the AI use cases that health systems are prioritizing over the next few years includes findings about plans for radiology AI that raise two important questions for neuroradiologists and healthcare leaders: Based on a survey of 58 executives and senior managers at“Health system priorities for AI and two important questions for radiology leaders”

read more

News

STAGE and the Promise and Challenges of New Alzheimer’s Drug Therapies

Radiologists, neurologists, Alzheimer’s patients and their families are rightfully encouraged by the range of new drugs in development to slow or reduce cognitive decline. At the start of 2023 there were 187 trials for 141 drugs addressing Alzheimer’s pathologies. Two drugs, aducanumab and lecanemab, have received accelerated FDA approval in the past two years. A“STAGE and the Promise and Challenges of New Alzheimer’s Drug Therapies”

read more

SpinTech MRI

30200 Telegraph Rd., Suite 140
Bingham Farms, MI 48025

Email: info@spintechmri.com

Tel: +1 (248) 712 6789